Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform’s award-winning CESS® technology can deliver to its drug development projects.
The two parties have executed a master services agreement (MSA) to initiate projects in the pre-clinical early development space with the aim of solving the ever-growing challenge of poor bioavailability and solubility in new drug candidates – a leading cause of drug development failure.
Christian Jones, CCO of Nanoform, commented:
“Wider uptake of the latest technological innovations is essential to address the low success rates for new drug candidates in Pharma. We are delighted to collaborate with Boehringer Ingelheim to evaluate how our proprietary CESS® platform can help more novel therapies reach the patients who need them. This is the first step toward what we hope will be a long and fruitful partnership between our companies.”
We’re delighted that Christian Jones, the Chief Commercial Officer of Nanoform will be speaking on the “It’s all in the delivery” session at Pharma Integrates on 16th November, 2021.
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications.